Infliximab
Infliximab is a therapeutic monoclonal antibody used in the treatment of immune-mediated inflammatory diseases.
Infliximab is a therapeutic monoclonal antibody used in the treatment of immune-mediated inflammatory diseases. It is best known as an anti-TNFα biologic, meaning it binds tumor necrosis factor alpha and helps suppress downstream inflammatory signaling. Clinically, this mechanism has made infliximab an important therapy in conditions such as inflammatory bowel disease and other chronic inflammatory disorders in which TNF-driven immune activation contributes to tissue damage.
Because infliximab modulates a central inflammatory pathway, it is also a useful reference drug in translational research on biologic efficacy, safety, biosimilar switching, and mechanisms of treatment resistance. Recent studies have continued to use infliximab as a comparator, a treatment intervention, or a mechanistic benchmark alongside other biologics such as adalimumab, etanercept, ixekizumab, risankizumab, and ustekinumab.
Where the papers sit
12 papers from the last 6 months study infliximab directly · updated from PubMed 8 Oct 2026
Study type 1 clinical trial · 6 observational · 2 human data · 2 preclinical · 1 unclassified
Themes one subject · 1 new direction
Those 12 are all about one subject.
-
Anti-TNF Therapy
Anti-TNF therapy is moving toward model-informed dosing, assay harmonization, and tighter benefit–risk assessment rather than simple expansion of use. In IBD, pharmacokinetic models, therapeutic-drug monitoring, biosimilar switching, and comparisons with adalimumab address exposure, effectiveness, and heart-failure risk. Exploratory work tests infliximab in acute pancreatitis and examines vascular effects and granulomatous complications. Formulation and antibody-engineering studies target oligomerization and conditional activation, but no single approach yet dominates.
Infliximab is treated as a formulation-dependent oligomerization analyte, not only as a therapeutic antibody
The therapeutic-protein formulation study using a dynamic-light-scattering hydrodynamic-molecular-weight model examined infliximab as a monoclonal-antibody formulation rather than solely as a clinical treatment or monitoring target 42373916Jun. Whereas the other papers use infliximab in therapeutic, pharmacokinetic, safety, or assay contexts, this study found that its hydrodynamic molecular weight was several-fold greater than its monomeric molecular weight, indicating oligomerization. This gives infliximab a distinct formulation-quality role in which higher-order structure becomes a measurable determinant of protein stability, safety, and efficacy.
Papers
The 12 papers from the last 6 months that study infliximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Anti-TNF Therapy (12)
- Crohn's disease unmasks pulmonary sarcoidosis on biologic screening: dual granulomatous pathology responsive to infliximab. BMJ case reports · 28 Sept 2026 PMID 42805621
- Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). BMJ open · 18 Sept 2026 PMID 42760074
- Sex Differences in Growth Recovery among Children with Crohn's Disease. Gut and liver · 31 Aug 2026 PMID 42670695
- Bridging the Gap Between Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry for Infliximab Monitoring: Method Validation and Clinical Comparability Study. Journal of separation science · 29 Aug 2026 PMID 42667246
- Infliximab-associated sarcoid-like reaction and haemophagocytic lymphohistiocytosis in multisystem sarcoidosis. BMJ case reports · 19 Aug 2026 PMID 42618309
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PloS one · 24 Jul 2026 PMID 42497217
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
- Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
- The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439
- A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodies. mAbs · 7 May 2026 PMID 42093183
By study type
Clinical trials (1)
- Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). BMJ open · 18 Sept 2026 PMID 42760074
Observational studies and case reports (6)
- Crohn's disease unmasks pulmonary sarcoidosis on biologic screening: dual granulomatous pathology responsive to infliximab. BMJ case reports · 28 Sept 2026 PMID 42805621
- Sex Differences in Growth Recovery among Children with Crohn's Disease. Gut and liver · 31 Aug 2026 PMID 42670695
- Infliximab-associated sarcoid-like reaction and haemophagocytic lymphohistiocytosis in multisystem sarcoidosis. BMJ case reports · 19 Aug 2026 PMID 42618309
- Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PloS one · 24 Jul 2026 PMID 42497217
- Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database. Proceedings (Baylor University. Medical Center) · 10 Jun 2026 PMID 42269048
- The Longer-Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population-Based Study. Pharmacoepidemiology and drug safety · 20 May 2026 PMID 42157439
Human data, design not indexed (2)
- Bridging the Gap Between Chemiluminescence Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry for Infliximab Monitoring: Method Validation and Clinical Comparability Study. Journal of separation science · 29 Aug 2026 PMID 42667246
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
Preclinical: animal, cell and lab studies (2)
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodies. mAbs · 7 May 2026 PMID 42093183
Unclassified: not yet indexed with MeSH (1)
- Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.